TY - JOUR T1 - Automated lung sound analysis using the LungPass platform: A sensitive and specific tool for identifying lower respiratory tract involvement in COVID-19 JF - medRxiv DO - 10.1101/2021.07.08.21260125 SP - 2021.07.08.21260125 AU - Elena A. Lapteva AU - Olga N. Kharevich AU - Victoria V. Khatsko AU - Natalia A. Voronova AU - Maksim V. Chamko AU - Irina V. Bezruchko AU - Elena I. Katibnikova AU - Elena I. Loban AU - Mostafa M. Mouawie AU - Helena Binetskaya AU - Sergey Aleshkevich AU - Aleksey Karankevich AU - Vitaly Dubinetski AU - Jørgen Vestbo AU - Alexander G. Mathioudakis Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/08/2021.07.08.21260125.abstract N2 - Background Lower respiratory tract (LRT) involvement, observed in about 20% of patients suffering from coronavirus disease 2019 (COVID-19) is associated with a more severe clinical course, adverse outcomes and long-term sequelae. Early identification of LRT involvement could facilitated targeted and timely interventions that could alter the short- and long-term disease outcomes. The LungPass is an automated lung sound analysis platform developed using neural network technology and previously trained. We hypothesised that the LungPass could be used as a screening tool for LRT involvement in patients with COVID-19.Methods In a prospective observational study involving 282 individuals with presenting in the emergency department with a strong clinical suspicion of COVID-19 and imaging findings consistent with COVID-19 LRT involvement (25.5% had concomitant hypoxia), and 32 healthy controls, we assessed the sensitivity and specificity of the LungPass in identifying LRT involvement in COVID-19. We also compared the auscultatory findings of the LungPass compared to a chest physician using a traditional, high-quality stethoscope.Results Among individuals with COVID-19 LRT involvement, the LungPass identified crackles in at least one auscultation site in 93.6% and in two or more points in 84%. Moreover, the LungPass identified any abnormal lung sound (crackles or wheeze) in at least one auscultation site in 98.6% and in at least two points in 94% of the participants. The respective percentages for the respiratory physicians were lower.Considering the presence of any added abnormal sound (crackles or wheeze) in at least two auscultation points as evidence of LRT involvement, LungPass demonstrated a sensitivity of 98.6% (95% confidence intervals [CI]: 96.4%-99.6%) and a specificity of 96.9% (95% CI: 83.8%-99.9%) in identifying COVID-19 LRT involvement.Conclusion This exploratory study suggests the LungPass is a sensitive and specific platform for identifying LRT involvement due to COVID-19, even before the development of hypoxia.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form summarizing any conflicts of interest they may have. EAL, OK, EIL, MMM, HB, SA, AK and VD are employed by Healthy Networks OU. EAL HB, AK, VD and AGM hold shares in Healthy Networks. VVK, NAV, MVC, IB and EIK have received personal fees from Healthy Network, related to this work. Other potential conflicts of interest outside the submitted work are summarized in the attached CoI declaration forms. JV reports personal fees from AstraZeneca, grants and personal fees from Boehringer-Ingelheim, personal fees from Chiesi, GSK and Novartis, outside the submitted work; his son works for Chiesi. AGM reports grants from Boehringer Ingelheim outsde the submitted work.Funding StatementThis study was funded and sponsored by Healthy Networks.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by Belarusian State Medical Academy of Postgraduate Education Ethics Committee (Ethics Committee Reference number: №18/21012020) at its meeting held on 06.02.2020 (Protocol № 1/2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAccess to de-identified patient level data is available upon request to the authors. Lung sounds cannot be shared as they are protected IP owned by the Healthy Network OU ER -